{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T09:26:52Z","timestamp":1750325212645,"version":"3.37.3"},"reference-count":127,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Oncology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.yao.2024.01.001","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T20:38:46Z","timestamp":1706560726000},"page":"111-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic and Theranostic Opportunities in Neuro-Oncology"],"prefix":"10.1016","volume":"4","author":[{"given":"Zsombor","family":"Ritter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Oeltzschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilja Bjork","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Olayinka","family":"Kamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2217\/17435889.3.2.137","article-title":"Theranostic nanomedicine for cancer","volume":"3","author":"Sumer","year":"2008","journal-title":"Nanomedicine"},{"issue":"11","key":"10.1016\/j.yao.2024.01.001_bib2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"issue":"Supplement_5","key":"10.1016\/j.yao.2024.01.001_bib3","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of Brain Metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib5","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.3171\/2023.5.FOCUS23212","article-title":"Epidemiology and survival outcomes of synchronous and metachronous brain metastases: a retrospective population-based study","volume":"55","author":"Jiang","year":"2023","journal-title":"Neurosurg Focus"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib6","doi-asserted-by":"crossref","first-page":"vdad015","DOI":"10.1093\/noajnl\/vdad015","article-title":"Epidemiological trends, prognostic factors, and survival outcomes of synchronous brain metastases from 2015 to 2019: a population-based study","volume":"5","author":"Parker","year":"2023","journal-title":"Neuro-Oncology Advances"},{"issue":"10","key":"10.1016\/j.yao.2024.01.001_bib7","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/neuonc\/noaa142","article-title":"Baseline requirements for novel agents being considered for phase II\/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium\u2019s first workshop on CNS drug delivery","volume":"22","author":"Grossman","year":"2020","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.yao.2024.01.001_bib8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1750-3639.2008.00195.x","article-title":"Brain Extracellular Matrix in Neurodegeneration","volume":"19","author":"Bonneh-Barkay","year":"2009","journal-title":"Brain Pathol"},{"issue":"8","key":"10.1016\/j.yao.2024.01.001_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","article-title":"Challenges to curing primary brain tumours","volume":"16","author":"Aldape","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"1\u20132","key":"10.1016\/j.yao.2024.01.001_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","article-title":"Blood\u2013brain barrier delivery","volume":"12","author":"Pardridge","year":"2007","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.yao.2024.01.001_bib12","doi-asserted-by":"crossref","first-page":"1254955","DOI":"10.3389\/fmed.2023.1254955","article-title":"Druggable genomic landscapes of high-grade gliomas","volume":"10","author":"Ghanem","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"10.1016\/j.yao.2024.01.001_bib13","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41591-018-0044-4","article-title":"STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis","volume":"24","author":"Priego","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.yao.2024.01.001_bib14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/archneurol.2011.2910","article-title":"Addressing diffuse glioma as a systemic brain disease with single-cell analysis","volume":"69","author":"Sahm","year":"2012","journal-title":"Arch Neurol"},{"issue":"7_Supplement","key":"10.1016\/j.yao.2024.01.001_bib15","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1158\/1538-7445.AM2023-4483","article-title":"Abstract 4483: Distinct spatial distribution patterns of ALK-inhibitor na\u00efve versus ALK-inhibitor treated ALK-positive NSCLC brain metastases","volume":"83","author":"Cheunkarndee","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-013-1043-4","article-title":"Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates","volume":"112","author":"Kamson","year":"2013","journal-title":"J\u00a0Neuro Oncol"},{"issue":"8","key":"10.1016\/j.yao.2024.01.001_bib17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.trecan.2019.06.003","article-title":"Improving CNS Delivery to Brain Metastases by Blood\u2013Tumor Barrier Disruption","volume":"5","author":"Sprowls","year":"2019","journal-title":"Trends in Cancer"},{"issue":"37","key":"10.1016\/j.yao.2024.01.001_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103280118","article-title":"Localized blood\u2013brain barrier opening in infiltrating gliomas with MRI-guided acoustic emissions\u2013controlled focused ultrasound","volume":"118","author":"Anastasiadis","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.yao.2023.01.017","article-title":"Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas","volume":"3","author":"Gould","year":"2023","journal-title":"Advances in Oncology"},{"key":"10.1016\/j.yao.2024.01.001_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ctro.2022.04.013","article-title":"Blood-brain barrier permeability following conventional photon radiotherapy \u2013 A systematic review and meta-analysis of clinical and reclinical studies","volume":"35","author":"Hart","year":"2022","journal-title":"Clinical and Translational Radiation Oncology"},{"key":"10.1016\/j.yao.2024.01.001_bib21","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jconrel.2022.08.051","article-title":"Recent advances in drug delivery and targeting to the brain","volume":"350","author":"Sethi","year":"2022","journal-title":"J\u00a0Contr Release"},{"issue":"3","key":"10.1016\/j.yao.2024.01.001_bib22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00259-016-3494-2","article-title":"The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma","volume":"44","author":"Poulsen","year":"2017","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"6","key":"10.1016\/j.yao.2024.01.001_bib23","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.2310\/7290.2014.00015","article-title":"Comparison of Amino Acid Positron Emission Tomographic Radiotracers for Molecular Imaging of Primary and Metastatic Brain Tumors","volume":"13","author":"Juh\u00e1sz","year":"2014","journal-title":"Mol Imag"},{"issue":"3","key":"10.1016\/j.yao.2024.01.001_bib24","doi-asserted-by":"crossref","first-page":"e4649","DOI":"10.1002\/nbm.4649","article-title":"Dynamic contrast-enhanced CEST MRI using a low molecular weight dextran","volume":"35","author":"Han","year":"2022","journal-title":"NMR Biomed"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib25","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/mrm.27014","article-title":"Characterization of tumor vascular permeability using natural dextrans and CEST MRI","volume":"79","author":"Li","year":"2018","journal-title":"Magn Reson Med"},{"issue":"6","key":"10.1016\/j.yao.2024.01.001_bib26","doi-asserted-by":"crossref","first-page":"6369","DOI":"10.18632\/oncotarget.7141","article-title":"CEST theranostics: label-free MR imaging of anticancer drugs","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.yao.2024.01.001_bib27","doi-asserted-by":"crossref","first-page":"1077461","DOI":"10.3389\/fonc.2023.1077461","article-title":"In-vivo magnetic resonance spectroscopy of lactate as a non-invasive biomarker of dichloroacetate activity in cancer and non-cancer central nervous system disorders","volume":"13","author":"Kamson","year":"2023","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.yao.2024.01.001_bib28","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1158\/1078-0432.CCR-19-2808","article-title":"First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K\/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma","volume":"26","author":"Wen","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.yao.2024.01.001_bib29","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/ph14090872","article-title":"Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview","volume":"14","author":"Cimini","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","article-title":"Auger electrons for cancer therapy \u2013 a review","volume":"4","author":"Ku","year":"2019","journal-title":"EJNMMI radiopharm chem"},{"issue":"6","key":"10.1016\/j.yao.2024.01.001_bib31","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1148\/rg.2020200021","article-title":"Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology","volume":"40","author":"Gomes Marin","year":"2020","journal-title":"Radiographics"},{"issue":"4","key":"10.1016\/j.yao.2024.01.001_bib32","first-page":"e220157","article-title":"A\u00a0Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements","volume":"5","author":"Burkett","year":"2023","journal-title":"Radiology: Imaging Cancer"},{"key":"10.1016\/j.yao.2024.01.001_bib33","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.2147\/OTT.S140671","article-title":"Theranostics in nuclear medicine practice","volume":"10","author":"Yordanova","year":"2017","journal-title":"OTT"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/snuc.2002.31022","article-title":"Somatostatin receptor imaging","volume":"32","author":"Kwekkeboom","year":"2002","journal-title":"Semin Nucl Med"},{"issue":"14","key":"10.1016\/j.yao.2024.01.001_bib35","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.2217\/fon.14.139","article-title":"PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature","volume":"10","author":"Johnbeck","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.yao.2024.01.001_bib36","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clinimag.2019.04.006","article-title":"Molecular imaging and therapy of somatostatin receptor positive tumors","volume":"56","author":"Ivanidze","year":"2019","journal-title":"Clin Imag"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.yao.2024.01.001_bib38","first-page":"2578","article-title":"Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177 Lu-Dotatate in the Phase III NETTER-1 Trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J\u00a0Clin Orthod"},{"issue":"12","key":"10.1016\/j.yao.2024.01.001_bib39","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.yao.2024.01.001_bib40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.rcl.2021.01.005","article-title":"Cellular and Molecular Imaging with SPECT and PET in Brain Tumors","volume":"59","author":"Sadaghiani","year":"2021","journal-title":"Radiol Clin"},{"issue":"9","key":"10.1016\/j.yao.2024.01.001_bib41","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.21037\/qims.2019.08.16","article-title":"An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care","volume":"9","author":"Shooli","year":"2019","journal-title":"Quant Imag Med Surg"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13014-021-01875-6","article-title":"68Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas","volume":"16","author":"Kowalski","year":"2021","journal-title":"Radiat Oncol"},{"issue":"5","key":"10.1016\/j.yao.2024.01.001_bib43","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/RLU.0000000000003599","article-title":"Feasibility and Therapeutic Potential of Peptide Receptor Radionuclide Therapy for High-Grade Gliomas","volume":"46","author":"Nemati","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1016\/j.yao.2024.01.001_bib44","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.oooo.2018.01.011","article-title":"Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET\/CT","volume":"125","author":"Klein","year":"2018","journal-title":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"},{"issue":"11","key":"10.1016\/j.yao.2024.01.001_bib45","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","article-title":"The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET\/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions","volume":"56","author":"Afshar-Oromieh","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"10","key":"10.1016\/j.yao.2024.01.001_bib46","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1097\/RLU.0000000000001769","article-title":"Prostate-Specific Membrane Antigen\u2013Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas","volume":"42","author":"Salas Fragomeni","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"9","key":"10.1016\/j.yao.2024.01.001_bib47","first-page":"919","article-title":"PSMA expression on neovasculature of solid tumors","volume":"35","year":"2020","journal-title":"Histol Histopathol"},{"issue":"13","key":"10.1016\/j.yao.2024.01.001_bib48","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic Performance of 18F-DCFPyL-PET\/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.yao.2024.01.001_bib49","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of Hybrid 68 Ga-PSMA Ligand PET\/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"12","key":"10.1016\/j.yao.2024.01.001_bib50","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.yao.2024.01.001_bib51","first-page":"5000","article-title":"TheraP: 177 Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel\u2014Overall survival after median follow-up of 3 years (ANZUP 1603)","volume":"40","author":"Hofman","year":"2022","journal-title":"J\u00a0Clin Orthod"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11060-023-04355-x","article-title":"Identification of incidental brain tumors in prostate cancer patients via PSMA PET\/CT","volume":"163","author":"McLaughlin","year":"2023","journal-title":"J\u00a0Neuro Oncol"},{"issue":"3","key":"10.1016\/j.yao.2024.01.001_bib53","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.18632\/oncotarget.13994","article-title":"Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST","volume":"8","author":"Heitk\u00f6tter","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.yao.2024.01.001_bib54","doi-asserted-by":"crossref","first-page":"774017","DOI":"10.3389\/fonc.2021.774017","article-title":"PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook","volume":"11","author":"Kirchner","year":"2021","journal-title":"Front Oncol"},{"issue":"25","key":"10.1016\/j.yao.2024.01.001_bib55","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1038\/s41388-019-0765-y","article-title":"Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment","volume":"38","author":"Bu","year":"2019","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.yao.2024.01.001_bib56","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A\u00a0Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.yao.2024.01.001_bib57","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3390\/ph16040521","article-title":"Head-to-Head Comparison between [68Ga]Ga-DOTA.SA.FAPi and [18F]F-FDG PET\/CT Imaging in Patients with Breast Cancer","volume":"16","author":"Ballal","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib58","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1148\/radiol.211424","article-title":"Comparison of 68 Ga-FAPI and 18 F-FDG PET\/CT in the Evaluation of Advanced Lung Cancer","volume":"303","author":"Wang","year":"2022","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.yao.2024.01.001_bib59","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.7150\/thno.69475","article-title":"Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review","volume":"12","author":"Zhao","year":"2022","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.yao.2024.01.001_bib60","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.122.265215","article-title":"Superior Tumor Detection for 68 Ga-FAPI-46 Versus 18 F-FDG PET\/CT and Conventional CT in Patients with Cholangiocarcinoma","volume":"64","author":"Pabst","year":"2023","journal-title":"J\u00a0Nucl Med"},{"issue":"10","key":"10.1016\/j.yao.2024.01.001_bib61","doi-asserted-by":"crossref","first-page":"13961","DOI":"10.1007\/s13277-016-5274-9","article-title":"Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma","volume":"37","author":"Busek","year":"2016","journal-title":"Tumor Biol"},{"key":"10.1016\/j.yao.2024.01.001_bib62","doi-asserted-by":"crossref","first-page":"109021","DOI":"10.1016\/j.ejrad.2020.109021","article-title":"FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas","volume":"127","author":"R\u00f6hrich","year":"2020","journal-title":"Eur J Radiol"},{"issue":"12","key":"10.1016\/j.yao.2024.01.001_bib63","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s00259-019-04444-y","article-title":"IDH-wildtype glioblastomas and grade III\/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein\u2013specific PET\/CT","volume":"46","author":"R\u00f6hrich","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.yao.2024.01.001_bib64","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cpet.2021.03.005","article-title":"Theranostics in Brain Tumors","volume":"16","author":"Shooli","year":"2021","journal-title":"Pet Clin"},{"issue":"5","key":"10.1016\/j.yao.2024.01.001_bib65","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0306-3623(94)00292-U","article-title":"The mammalian tachykinin receptors","volume":"26","author":"Maggi","year":"1995","journal-title":"Gen Pharmacol Vasc Syst"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.semnuclmed.2019.11.004","article-title":"225Ac- and 213Bi-Substance P Analogues for Glioma Therapy","volume":"50","author":"Kr\u00f3licki","year":"2020","journal-title":"Semin Nucl Med"},{"issue":"7","key":"10.1016\/j.yao.2024.01.001_bib67","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00259-010-1385-5","article-title":"Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial","volume":"37","author":"Cordier","year":"2010","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib68","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1021\/cbmi.3c00019","article-title":"Label-Free Chemically and Molecularly Selective Magnetic Resonance Imaging","volume":"1","author":"Wu","year":"2023","journal-title":"Chemical & Biomedical Imaging"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib69","doi-asserted-by":"crossref","first-page":"024103","DOI":"10.1088\/1748-605X\/abdd70","article-title":"CEST MRI trackable nanoparticle drug delivery systems","volume":"16","author":"Han","year":"2021","journal-title":"Biomed Mater"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/ph14010011","article-title":"Repurposing Clinical Agents for Chemical Exchange Saturation Transfer Magnetic Resonance Imaging: Current Status and Future Perspectives","volume":"14","author":"Chen","year":"2020","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.yao.2024.01.001_bib71","doi-asserted-by":"crossref","first-page":"e4715","DOI":"10.1002\/nbm.4715","article-title":"A\u00a0snapshot of the vast array of diamagnetic CEST MRI contrast agents","volume":"36","author":"Longo","year":"2023","journal-title":"NMR Biomed"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib72","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/pharmaceutics14020451","article-title":"Molecular Imaging of Brain Tumors and Drug Delivery Using CEST MRI: Promises and Challenges","volume":"14","author":"Huang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.yao.2024.01.001_bib73","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1021\/acs.molpharmaceut.6b00130","article-title":"Imaging the DNA Alkylator Melphalan by CEST MRI: An Advanced Approach to Theranostics","volume":"13","author":"Ngen","year":"2016","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.yao.2024.01.001_bib74","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.7150\/thno.15492","article-title":"Label-free CEST MRI Detection of Citicoline-Liposome Drug Delivery in Ischemic Stroke","volume":"6","author":"Liu","year":"2016","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.yao.2024.01.001_bib75","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1021\/acsabm.1c00411","article-title":"Imaging Self-Healing Hydrogels and Chemotherapeutics Using CEST MRI at 3 T","volume":"4","author":"Han","year":"2021","journal-title":"ACS Appl Bio Mater"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib76","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/acsnano.6b07196","article-title":"One-Component Supramolecular Filament Hydrogels as Theranostic Label-Free Magnetic Resonance Imaging Agents","volume":"11","author":"Lock","year":"2017","journal-title":"ACS Nano"},{"issue":"29","key":"10.1016\/j.yao.2024.01.001_bib77","doi-asserted-by":"crossref","first-page":"9871","DOI":"10.1002\/anie.201904722","article-title":"Carbon Dots as a New Class of Diamagnetic Chemical Exchange Saturation Transfer (diaCEST) MRI Contrast Agents","volume":"58","author":"Zhang","year":"2019","journal-title":"Angew Chem Int Ed"},{"issue":"4","key":"10.1016\/j.yao.2024.01.001_bib78","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1021\/acs.nanolett.5b04517","article-title":"Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI NanoPlatform","volume":"16","author":"Lesniak","year":"2016","journal-title":"Nano Lett"},{"issue":"12","key":"10.1016\/j.yao.2024.01.001_bib79","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41563-019-0503-4","article-title":"Furin-mediated intracellular self-assembly of olsalazine nanoparticles for enhanced magnetic resonance imaging and tumour therapy","volume":"18","author":"Yuan","year":"2019","journal-title":"Nat Mater"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib80","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/mrm.27180","article-title":"MRI detection of bacterial brain abscesses and monitoring of antibiotic treatment using bacCEST","volume":"80","author":"Liu","year":"2018","journal-title":"Magn Reson Med"},{"issue":"6","key":"10.1016\/j.yao.2024.01.001_bib81","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/mrm.24955","article-title":"Noninvasive imaging of infection after treatment with tumor-homing bacteria using Chemical Exchange Saturation Transfer (CEST) MRI","volume":"70","author":"Liu","year":"2013","journal-title":"Magn Reson Med"},{"issue":"3","key":"10.1016\/j.yao.2024.01.001_bib82","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1148\/radiol.14140251","article-title":"Establishing the Lysine-rich Protein CEST Reporter Gene as a CEST MR Imaging Detector for Oncolytic Virotherapy","volume":"275","author":"Farrar","year":"2015","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib83","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1038\/s41598-018-22993-4","article-title":"Non-invasive detection of adeno-associated viral gene transfer using a genetically encoded CEST-MRI reporter gene in the murine heart","volume":"8","author":"Meier","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.yao.2024.01.001_bib84","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/jcbfm.2014.12","article-title":"Quantitative Tissue Ph Measurement during Cerebral Ischemia Using Amine and Amide Concentration-Independent Detection (AACID) with MRI","volume":"34","author":"McVicar","year":"2014","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib85","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-017-2664-9","article-title":"Dichloroacetate induced intracellular acidification in glioblastoma: in\u00a0vivo detection using AACID-CEST MRI at 9.4 Tesla","volume":"136","author":"Albatany","year":"2018","journal-title":"J\u00a0Neuro Oncol"},{"issue":"5","key":"10.1016\/j.yao.2024.01.001_bib86","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/nbm.3287","article-title":"Imaging chemical exchange saturation transfer (CEST) effects following tumor-selective acidification using lonidamine","volume":"28","author":"McVicar","year":"2015","journal-title":"NMR Biomed"},{"issue":"3","key":"10.1016\/j.yao.2024.01.001_bib87","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11060-016-2258-y","article-title":"Topiramate induces acute intracellular acidification in glioblastoma","volume":"130","author":"Marathe","year":"2016","journal-title":"J\u00a0Neuro Oncol"},{"issue":"7","key":"10.1016\/j.yao.2024.01.001_bib88","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3390\/metabo13070823","article-title":"Intracellular Acidification in a Rat C6 Glioma Model following Cariporide Injection Investigated by CEST-MRI","volume":"13","author":"Mozaffari","year":"2023","journal-title":"Metabolites"},{"issue":"3","key":"10.1016\/j.yao.2024.01.001_bib89","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11060-019-03132-z","article-title":"pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma","volume":"142","author":"Yao","year":"2019","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.yao.2024.01.001_bib90","doi-asserted-by":"crossref","first-page":"102882","DOI":"10.1016\/j.nicl.2021.102882","article-title":"\u201cAerobic glycolytic imaging\u201d of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging","volume":"32","author":"Hagiwara","year":"2021","journal-title":"Neuroimage"},{"key":"10.1016\/j.yao.2024.01.001_bib91","article-title":"pH-Weighted amine chemical exchange saturation transfer echo planar imaging visualizes infiltrating glioblastoma cells","author":"Patel","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib92","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/mrm.27439","article-title":"Machine learning improves classification of preclinical models of pancreatic cancer with chemical exchange saturation transfer MRI","volume":"81","author":"Goldenberg","year":"2019","journal-title":"Magn Reson Med"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib93","doi-asserted-by":"crossref","first-page":"e4626","DOI":"10.1002\/nbm.4626","article-title":"Deep learning-based classification of preclinical breast cancer tumor models using chemical exchange saturation transfer magnetic resonance imaging","volume":"35","author":"Bie","year":"2022","journal-title":"NMR Biomed"},{"issue":"5","key":"10.1016\/j.yao.2024.01.001_bib94","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41551-021-00809-7","article-title":"Quantitative imaging of apoptosis following oncolytic virotherapy by magnetic resonance fingerprinting aided by deep learning","volume":"6","author":"Perlman","year":"2021","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"10.1016\/j.yao.2024.01.001_bib95","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11912-021-01020-2","article-title":"Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors","volume":"23","author":"Overcast","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"10.1016\/j.yao.2024.01.001_bib96","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 Mutations in Gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"5897","key":"10.1016\/j.yao.2024.01.001_bib97","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An Integrated Genomic Analysis of Human Glioblastoma Multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.yao.2024.01.001_bib98","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"7274","key":"10.1016\/j.yao.2024.01.001_bib99","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.yao.2024.01.001_bib100","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.2682","article-title":"2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas","volume":"18","author":"Choi","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib101","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s41467-018-03905-6","article-title":"Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in\u00a0vivo 3D MRS imaging of 2-hydroxyglutarate","volume":"9","author":"Andronesi","year":"2018","journal-title":"Nat Commun"},{"issue":"116","key":"10.1016\/j.yao.2024.01.001_bib102","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002796","article-title":"Magnetic Resonance of 2-Hydroxyglutarate in IDH1 -Mutated Low-Grade Gliomas","volume":"4","author":"Elkhaled","year":"2012","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.yao.2024.01.001_bib103","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11060-011-0737-8","article-title":"Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy","volume":"107","author":"Pope","year":"2012","journal-title":"J\u00a0Neuro Oncol"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib104","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/neuonc\/nov307","article-title":"Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma","volume":"18","author":"De La Fuente","year":"2016","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.yao.2024.01.001_bib105","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/neuonc\/nox214","article-title":"Highly specific determination of IDH status using edited in\u00a0vivo magnetic resonance spectroscopy","volume":"20","author":"Branzoli","year":"2018","journal-title":"Neuro Oncol"},{"issue":"9","key":"10.1016\/j.yao.2024.01.001_bib106","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/neuonc\/noy022","article-title":"Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas","volume":"20","author":"Zhou","year":"2018","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib107","first-page":"391","article-title":"Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting","volume":"128","author":"Tietze","year":"2018","journal-title":"J\u00a0Neurosurg"},{"issue":"33","key":"10.1016\/j.yao.2024.01.001_bib108","first-page":"4030","article-title":"Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH -Mutant Glioma","volume":"34","author":"Choi","year":"2016","journal-title":"J\u00a0Clin Orthod"},{"issue":"7","key":"10.1016\/j.yao.2024.01.001_bib109","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1158\/1078-0432.CCR-15-0656","article-title":"Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate","volume":"22","author":"Andronesi","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.yao.2024.01.001_bib110","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","article-title":"Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial","volume":"29","author":"Mellinghoff","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.yao.2024.01.001_bib111","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-23-0585","article-title":"Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase\u2013mutant Astrocytic and Oligodendroglial Tumors","author":"Kamson","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.yao.2024.01.001_bib112","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1158\/1078-0432.CCR-23-2164","article-title":"Glioma Response to IDH Inhibition: Real-World Experience","volume":"29","author":"Lukas","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.yao.2024.01.001_bib113","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/03602539808996323","article-title":"Pharmacokinetics, Metabolism, and Toxicology of Dichloroacetate","volume":"30","author":"Stacpoole","year":"1998","journal-title":"Drug Metabol Rev"},{"key":"10.1016\/j.yao.2024.01.001_bib114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/8201079","article-title":"Dichloroacetate (DCA) and Cancer: An Overvew towards Clinical Applications","volume":"2019","author":"Tataranni","year":"2019","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"10.1016\/j.yao.2024.01.001_bib115","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/jcbfm.1992.140","article-title":"Effect of Dichloroacetate on Recovery of Brain Lactate, Phosphorus Energy Metabolites, and Glutamate during Reperfusion after Complete Cerebral Ischemia in Rats","volume":"12","author":"Chang","year":"1992","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib116","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1442-200X.2009.02815.x","article-title":"Treatment for Leigh syndrome by monitoring dichloroacetate concentration","volume":"51","author":"Katsumi","year":"2009","journal-title":"Pediatr Int"},{"issue":"9","key":"10.1016\/j.yao.2024.01.001_bib117","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1212\/WNL.55.9.1376","article-title":"MR spectroscopy study of dichloroacetate treatment after ischemic stroke","volume":"55","author":"Graham","year":"2000","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.yao.2024.01.001_bib118","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1212\/WNL.45.6.1193","article-title":"Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders","volume":"45","author":"De Stefano","year":"1995","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.yao.2024.01.001_bib119","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/nbm.2935","article-title":"Measuring mitochondrial metabolism in rat brain in\u00a0vivo using MR Spectroscopy of hyperpolarized [2- 13 C]pyruvate","volume":"26","author":"Park","year":"2013","journal-title":"NMR Biomed"},{"issue":"5","key":"10.1016\/j.yao.2024.01.001_bib120","doi-asserted-by":"crossref","first-page":"e36197","DOI":"10.1371\/journal.pone.0036197","article-title":"The Ketogenic Diet Is an Effective Adjuvant to Radiation Therapy for the Treatment of Malignant Glioma","volume":"7","author":"Abdelwahab","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.yao.2024.01.001_bib121","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ijrobp.2020.06.021","article-title":"ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma","volume":"108","author":"Voss","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.yao.2024.01.001_bib122","doi-asserted-by":"crossref","first-page":"e953","DOI":"10.1212\/WNL.0000000000012386","article-title":"Feasibility and Biological Activity of a Ketogenic\/Intermittent-Fasting Diet in Patients With Glioma","volume":"97","author":"Schreck","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.yao.2024.01.001_bib123","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cmet.2016.07.010","article-title":"Nutritional Ketosis Alters Fuel Preference and Thereby Endurance Performance in Athletes","volume":"24","author":"Cox","year":"2016","journal-title":"Cell Metabol"},{"issue":"10","key":"10.1016\/j.yao.2024.01.001_bib124","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1097\/00004647-200010000-00012","article-title":"Human Brain \u03b2-Hydroxybutyrate and Lactate Increase in Fasting-Induced Ketosis","volume":"20","author":"Pan","year":"2000","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"key":"10.1016\/j.yao.2024.01.001_bib125","doi-asserted-by":"crossref","DOI":"10.3174\/ajnr.A6287","article-title":"Cerebral Ketones Detected by 3T MR Spectroscopy in Patients with High-Grade Glioma on an Atkins-Based Diet","author":"Berrington","year":"2019","journal-title":"AJNR Am J Neuroradiol"},{"issue":"11","key":"10.1016\/j.yao.2024.01.001_bib126","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1073\/pnas.1913042117","article-title":"Diet modulates brain network stability, a biomarker for brain aging, in young adults","volume":"117","author":"Mujica-Parodi","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.yao.2024.01.001_bib127","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41386-022-01364-8","article-title":"Acute administration of ketone beta-hydroxybutyrate downregulates 7T proton magnetic resonance spectroscopy-derived levels of anterior and posterior cingulate GABA and glutamate in healthy adults","volume":"48","author":"Hone-Blanchet","year":"2023","journal-title":"Neuropsychopharmacology"}],"container-title":["Advances in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666853X24000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666853X24000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T07:01:21Z","timestamp":1712646081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666853X24000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":127,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2666853X24000018"],"URL":"https:\/\/doi.org\/10.1016\/j.yao.2024.01.001","relation":{},"ISSN":["2666-853X"],"issn-type":[{"type":"print","value":"2666-853X"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic and Theranostic Opportunities in Neuro-Oncology","name":"articletitle","label":"Article Title"},{"value":"Advances in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yao.2024.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}